ClinicalTrials.gg
RecruitingNCT06626152LLDOPAUpdated Oct 3, 2024

Measuring Psychomotor Response to L-DOPA Challenge As a Biomarker for Outcomes in Late-Life Depression: a Pilot Feasibility Trial

A Phase 2 interventional study of Apo-levocarb in Major Depressive Disorder, sponsored by University of British Columbia. Recruiting at 1 site in Canada. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2024-10-03.

Sponsored by University of British Columbia · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by May 2026, 5 months ago, but the record still lists the study as recruiting.
  • Started Aug 2024; still recruiting 2 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Depressive Disorder, Major by University of British Columbia — 5 open to participants now, 7 under way, none of them phase 3. Depressive Disorder, Major · University of British Columbia.

Planned enrollment
9th of 15
50 · median 72
Started
2024
the only one that year
Phase 2
Only one
of the 16
Registered
15th of 16
by date

Among the 16 studies in Depressive Disorder, Major by University of British Columbia, this one is the 9th largest by planned enrollment of the 15 interventional ones that give a count, is the only one that started in 2024, is the only one in phase 2, and was the 15th registered.

Depressive Disorder, Major

3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

5 of the 16 studies in Depressive Disorder, Major by University of British Columbia are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.

This study: 60 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Depressive Disorder, Major by University of British Columbia, or all of them as a file.
02

Study summary

Background

Adults over the age of 60 with symptoms of major depressive disorder are said to have late-life depression (LLD), a condition that usually decreases a person's quality of life and is associated with other risks like physical frailty and dementia. A common feature of more severe LLD is psychomotor slowing, where a person's ability to think and move are impaired. For example, they might not be able to walk or process information as quickly, and they might have problems with their working memory.

Psychomotor slowing in LLD might be the result of a problem with the way a person's body produces or responds to the neurotransmitter dopamine. The drug Levodopa (L-DOPA), which can replace missing dopamine in the brain, has been used to treat to treat Parkinson's disease for many decades, and it might also affect psychomotor slowing in LLD.

Methods

In this study, participants are adults aged 60 years or older with moderate to severe major depression. Participants undergo the "L-DOPA challenge"-a 2-week period where they receive a dose of L-DOPA once a day for the first week and a dose of L-DOPA twice a day for the second week. Before and after a participant completes the L-DOPA challenge, the study team assesses their depressive symptoms and psychomotor function. After the L-DOPA challenge, if a participant still shows signs of moderate or severe depression, they receive an antidepressant for 12 weeks.

Aims

The first aim of this study is to test the feasibility of the L-DOPA challenge-that is, whether most of the 50 participants recruited for this study will complete the L-DOPA challenge. For example, participants might have to withdraw if they can't make the daily visits to the research site to receive their L-DOPA medication, if they can't tolerate the medication's side effects, or if their depressive symptoms get significantly worse. Our hypothesis is that 80% of the participants will complete the L-DOPA challenge.

The second aim of the study is to see if L-DOPA affects participants' depressive symptoms, processing speed, and working memory. Our hypothesis is that L-DOPA response, measured as an improvement in gait speed, is associated with a decrease in depressive symptoms and an increase in processing speed and working memory.

03

Conditions studied

  • Major Depressive Disorder
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Outpatient persons capable of providing
  • Minimum age of 60 years old
  • MINI International Neuropsychiatric Interview diagnosis of major depressive disorder, based on criteria
  • MADRS score of ≥15 (moderate/severe depression)
  • On stable doses of psychotropic medication, including antidepressant medication, for at least 4 weeks
  • Able to adhere to the intervention schedule

Exclusion criteria

Exclusion Criteria:

  • Current diagnosis of major neurocognitive disorder
  • Current active psychosis
  • Unstable medical illness, including clinical or laboratory evidence of uncompensated cardiovascular, endocrine, hematologic, hepatic, pulmonary (including bronchial asthma), or renal disease
  • Diagnosis of narrow angle glaucoma
  • Suspicious, undiagnosed skin lesions or a history of melanoma
  • History of myocardial infarction
  • Atrial, nodal, or ventricular arrhythmias
  • History of seizures or seizure disorder
  • History of peptic ulcer disease
  • History of allergy or other to levodopa, carbidopa, or to any other ingredient in the formulation of Levocarb
  • Active suicidal ideation
  • Psychotropic medication initiation or dose change \<4 weeks prior to enrolment
  • Regular use of dopamine antagonist or benzodiazepines ≥2mg lorazepam equivalent per day
  • Unable to complete neuropsychological testing in the English language
  • Have a non-correctable sensory impairment (i.e., cannot hear or see well enough to complete the neuropsychological tests)
  • History of falls, with ≥1 fall per week during the past 4 weeks
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    L-DOPA Challenge

    Participants will be administered a levodopa-carbidopa challenge, at a dosage of 150mg/37.5mg once daily for one week, followed by twice daily for one week. Psychomotor speed will be assessed before and after the challenge.

    Drug: Apo-levocarb

Interventions

  • DrugApo-levocarb

    As above.

06

What researchers measure

Primary outcomes

  1. L-DOPA challenge completion rate

    Number of participants who complete the 2-week challenge of receiving L-DOPA and post-challenge assessments

    Time frame: 6 months

  2. Depressive symptoms

    Change in depressive symptoms, as measured by the Montgomery-Åsberg Depression Rating Scale, after the L-DOPA challenge and after treatment for depression

    Time frame: At 2, 3, 7, and 15 weeks from baseline

  3. Gait speed

    Change in gait speed in response to L-DOPA, as measured by time to complete the 4-metre walk test.

    Time frame: At baseline and 2 weeks from baseline

  4. Psychomotor speed

    Changes in psychomotor speed in response to L-DOPA, as measured by the clinician-rated CORE instrument

    Time frame: At baseline and 2 weeks from baseline

Secondary outcomes

  1. Processing speed

    Change in processing speed, as measured by the NIH Toolbox Cognitive Battery: Pattern Comparison tool, after the L-DOPA challenge and after treatment for depression

    Time frame: At 2 and 15 weeks from baseline

  2. Working memory

    Change in working memory, as measured by the NIH Toolbox Cognitive Battery: List Sorting tool, after the L-DOPA challenge and after treatment for depression

    Time frame: At 2 and 15 weeks from baseline

  3. Side effects related to L-DOPA

    Incidence, frequency, and severity of side effects following L-DOPA administration, related to the cardiovascular, respiratory, musculoskeletal, genitourinary, skin, and central nervous systems, as recorded on an Adverse Effects Monitoring Form

    Time frame: At 2 weeks from baseline

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for May 2026, 21 months after the start.

Of 99 non-industry phase 2 interventional studies under Depressive Disorder, Major, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 57. This study's planned 21 months is below that.

Counting every sponsor, half of 198 studies reached it within 22 months; a quarter within 14 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 3, 2024
First posted
Oct 3, 2024
StartActual
Aug 15, 2024
Primary completionEst.
May 30, 2026
CompletionEst.
May 30, 2026
Last update
Oct 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06626152
Collaborators
Providence Health & Services
Responsible party
Kevin Smith (Clinical Assistant Professor, University of British Columbia) — Principal investigator
First posted
Oct 3, 2024
Start date
Aug 15, 2024
Primary completion
May 30, 2026 (estimated)
Completion
May 30, 2026 (estimated)
Last update
Oct 3, 2024

Study contacts

Nicholas J Ainsworth, MD
Contact
nainsworth@providencehealth.bc.ca
6048069090

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion